SCHEMBL3138923

SCHEMBL3138923

Nc1csc(S(N)(=O)=O)n1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CA2 P00918 15/20 0.40
CA1 P00915 13/20 0.40
CA9 Q16790 10/20 0.40
CA4 P22748 9/20 0.40
CA12 O43570 9/20 0.40
CA14 Q9ULX7 8/20 0.40
CA7 P43166 8/20 0.40
CA5A P35218 8/20 0.40
CA6 P23280 7/20 0.40
CA5B Q9Y2D0 6/20 0.40
CA13 Q8N1Q1 4/20 0.40
CA3 P07451 2/20 0.34
CSNK2A1 P68400 1/20 0.33
PLK3 Q9H4B4 1/20 0.33
USP2 O75604 1/20 0.30
TSHR P16473 1/20 0.30
TDP1 Q9NUW8 1/20 0.30
AGO2 Q9UKV8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9095722 0.76 NOS1 (0.46) CA2CA1CA9CA4CA12
SCHEMBL9365275 0.76 CA2 (0.36) CA2CA1CA9CA4CA12
SCHEMBL23531760 0.72 CA2 (0.34) CA2CA1CA9CA4CA12
SCHEMBL21777347 0.71 MEN1 (0.39) CA2CA1CA4CA12CA14
SCHEMBL21962305 0.71 CA2 (0.34) CA2CA1CA9CA4CA12
SCHEMBL20929927 0.71 CA2 (0.36) CA2CA1CA9CA4CA12
SCHEMBL19475418 0.70 CA2 (0.47) CA2CA1CA9CA4CA12
SCHEMBL10770545 0.70 CSNK2A1 (0.43) CA2CA1CA9CA4CA12
SCHEMBL19506114 0.70 CA2 (0.38) CA2CA1CA9CA4CA12
SCHEMBL19475490 0.69 CA2 (0.34) CA2CA1CA9CA4CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109996798-A N- [5- (aminosulfonyl) -4-methyl-1, 3-thiazol-2-yl ] -N-methyl-2- [4- (2-pyridinyl) -phenyl ] -acetamide free base hemihydrate, method for the production and use thereof 艾库里斯抗感染治疗有限公司 2019-07-09 CN claimed
CN-109996798-A N- [5- (aminosulfonyl) -4-methyl-1, 3-thiazol-2-yl ] -N-methyl-2- [4- (2-pyridinyl) -phenyl ] -acetamide free base hemihydrate, method for the production and use thereof 艾库里斯抗感染治疗有限公司 2019-07-09 CN disclosed
WO-2018095576-A1 TOPICAL PHARMACEUTICAL FORMULATION COMPRISING N-[5-(AMINOSULFONYL)-4-METHYL-1,3-THIAZOL-2-YL]-N-METHYL-2-[4-(2-PYRIDINYL)-PHENYL]-ACETAMIDE AICURIS ANTI-INFECTIVE CURES GMBH (DE) 2018-05-31 WO disclosed
US-20100004221-A1 THIAZEPINE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2010-01-07 US disclosed
EP-2119719-A1 THIAZEPINE DERIVATIVE Daiichi Sankyo Company, Limited (JP) 2009-11-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004221-A1 THIAZEPINE DERIVATIVE HSD11B1, HSD17B1, HSD3B1 CA2 1079/4885CA1 720/4885CA9 895/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.